Peringkat dalam Saham
#35075
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on... Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Harga Saham
$0.594
Terakhir disinkronkan: 2026-08-14
Kapitalisasi Pasar
$4.50M
Perubahan (1 tahun)
-66.44%
Perdagangan Mustang Bio, Inc. (MBIO)
Harga MBIO dengan kapitalisasi pasar B
Kapitalisasi pasar dari Mustang Bio, Inc.(MBIO)
Kapitalisasi Pasar: $4.50M
Per August 2026, Mustang Bio, Inc. memiliki kapitalisasi pasar sebesar $4.50M. Ini menjadikan Mustang Bio, Inc. sebagai perusahaan 35075th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Mustang Bio, Inc. dari 2017 hingga 2026
MBIO dibandingkan dengan 5 teratas stocks paling populer
| Harga MBIO |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.452T
|
+121,120,021.99%
|
|
|
|
|
$4.490T
|
+99,751,364.49%
|
|
|
|
|
$4.162T
|
+92,473,024.90%
|
|
|
|
|
$3.676T
|
+81,674,486.86%
|
|
|
|
|
$2.833T
|
+62,939,517.25%
|
